FDA-cleared profile

AutoContour (RADAC V5)

Radformation, Inc. · Radiotherapy Planning Imaging · FDA-cleared (510(k))

Authorized purpose: AutoContour Model RADAC V5 assists radiation treatment planners with contouring and reviewing structures in medical images for radiation therapy treatment planning. It produces initial machine-learning contours for user review and modification; it does not independently approve a contour or treatment plan.

Clinical role
Receives CT or MR image sets, generates initial structure contours, supports manual or automatic rigid registration and automatic deformable registration, presents contours for review and editing, and exports DICOM RTSTRUCT, REGISTRATION, and DOSE objects to the treatment-planning workflow.
Images and patients
Radiotherapy Planning Imaging · Multi-region
Key limitation
Keep in mind: Every generated contour and registration must be reviewed and edited as needed before planning use. FDA performance is model- and structure-specific: aggregate DSC and reviewer averages do not remove weak outliers, and several structure-level lower confidence bounds fall below the nominal size-category threshold. The summary describes training anatomy from adult male and female patients while its comparison table says any patient type with relevant scan data; pediatric, postsurgical, unusual-anatomy, positioning, contrast, and local-guideline performance therefore require local validation. Current vendor claims for CBCT and other v2.7 functions should not be assumed to be within this exact clearance unless confirmed against the applicable labeling.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: AutoContour Model RADAC V5 assists radiation treatment planners with contouring and reviewing structures in medical images for radiation therapy treatment planning. It produces initial machine-learning contours for user review and modification; it does not independently approve a contour or treatment plan.
  • Which images or clinical context are in scope?Modality: Radiotherapy Planning Imaging Anatomy or clinical context: Multi-region Input: DICOM CT or MR images for contouring or registration and fusion; PET/CT for registration or fusion only; and DICOM RTSTRUCT and REGISTRATION objects as supported inputs.
  • Who uses it?Intended users: Radiation treatment planners who are qualified to select, review, edit, and export contours. Procurement and governance should include radiation oncologists, dosimetrists, medical physicists, radiation therapists, and clinical IT according to local role assignments.
  • What does the software produce?Output: User-reviewed and editable contours plus DICOM RTSTRUCT, REGISTRATION, and DOSE files for downstream review in a treatment-planning or independent registration-QA system. The FDA summary states that the device has no built-in reporting.
  • What is its most important limitation?Key limitation: Every generated contour and registration must be reviewed and edited as needed before planning use. FDA performance is model- and structure-specific: aggregate DSC and reviewer averages do not remove weak outliers, and several structure-level lower confidence bounds fall below the nominal size-category threshold. The summary describes training anatomy from adult male and female patients while its comparison table says any patient type with relevant scan data; pediatric, postsurgical, unusual-anatomy, positioning, contrast, and local-guideline performance therefore require local validation. Current vendor claims for CBCT and other v2.7 functions should not be assumed to be within this exact clearance unless confirmed against the applicable labeling.

Clinical takeaway. Clinical role: AutoContour Model RADAC V5 assists radiation treatment planners with contouring and reviewing structures in medical images for radiation therapy treatment planning. It produces initial machine-learning contours for user review and modification; it does not independently approve a contour or treatment plan.

Evidence takeaway. Evidence from the reviewed source record: V5 has an exact FDA technical-validation package and independent product-family evidence from earlier versions. The evidence supports assisted contour generation with mandatory review; it does not establish autonomous use, universal generalizability, reduced toxicity, improved tumor control, or other patient outcomes.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
AutoContour Model RADAC V5 assists radiation treatment planners with contouring and reviewing structures in medical images for radiation therapy treatment planning. It produces initial machine-learning contours for user review and modification; it does not independently approve a contour or treatment plan.
  • Exact FDA submission
  • Checked 2026-09-04

Added in P2 round17 from the exact FDA decision material; later product-family claims remain separate.

Workflow role
Receives CT or MR image sets, generates initial structure contours, supports manual or automatic rigid registration and automatic deformable registration, presents contours for review and editing, and exports DICOM RTSTRUCT, REGISTRATION, and DOSE objects to the treatment-planning workflow.
  • Exact FDA submission
  • Checked 2026-09-02
Required input
DICOM CT or MR images for contouring or registration and fusion; PET/CT for registration or fusion only; and DICOM RTSTRUCT and REGISTRATION objects as supported inputs.
  • Exact FDA submission
  • Checked 2026-09-02
Output and clinician action
User-reviewed and editable contours plus DICOM RTSTRUCT, REGISTRATION, and DOSE files for downstream review in a treatment-planning or independent registration-QA system. The FDA summary states that the device has no built-in reporting.
  • Exact FDA submission
  • Checked 2026-09-02
Care setting
Professional radiation oncology treatment-planning workflows using DICOM-compatible imaging and treatment-planning systems.
  • Exact FDA submission
  • Checked 2026-09-02
Intended users
Radiation treatment planners who are qualified to select, review, edit, and export contours. Procurement and governance should include radiation oncologists, dosimetrists, medical physicists, radiation therapists, and clinical IT according to local role assignments.
  • Exact FDA submission
  • Checked 2026-09-02
Limitations
Every generated contour and registration must be reviewed and edited as needed before planning use. FDA performance is model- and structure-specific: aggregate DSC and reviewer averages do not remove weak outliers, and several structure-level lower confidence bounds fall below the nominal size-category threshold. The summary describes training anatomy from adult male and female patients while its comparison table says any patient type with relevant scan data; pediatric, postsurgical, unusual-anatomy, positioning, contrast, and local-guideline performance therefore require local validation. Current vendor claims for CBCT and other v2.7 functions should not be assumed to be within this exact clearance unless confirmed against the applicable labeling.
  • Exact FDA submission
  • Checked 2026-09-02
Evidence summary
V5 has an exact FDA technical-validation package and independent product-family evidence from earlier versions. The evidence supports assisted contour generation with mandatory review; it does not establish autonomous use, universal generalizability, reduced toxicity, improved tumor control, or other patient outcomes.
  • Exact FDA submission
  • Checked 2026-09-02

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
V5 has an exact FDA technical-validation package and independent product-family evidence from earlier versions. The evidence supports assisted contour generation with mandatory review; it does not establish autonomous use, universal generalizability, reduced toxicity, improved tumor control, or other patient outcomes.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-02
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-02

Sensitivity is not an applicable endpoint for this contour-generation device. Review the structure-specific DSC, distance, clinician-review, and local edit-burden evidence instead.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-02

Specificity is not an applicable endpoint for this contour-generation device. Review the structure-specific DSC, distance, clinician-review, and local edit-burden evidence instead.

FDA-listed CT contouring models

420 models

  • EndpointCT-based machine-learning contouring models listed for RADAC V5
  • PopulationHead and neck, thorax, abdomen, and pelvis structures in the K260509 comparison table
  • Tested versionAutoContour Model RADAC V5 cleared in K260509

FDA-listed MR contouring models

62 models

  • EndpointMR-based machine-learning contouring models listed for RADAC V5
  • PopulationMR structure models in the K260509 comparison table
  • Tested versionAutoContour Model RADAC V5 cleared in K260509

External CT mean DSC, small structures

0.73 DSC

  • EndpointMean Dice similarity coefficient across externally reviewed small CT structures
  • PopulationExternal CT image sets described in the K260509 validation summary
  • Tested versionAutoContour Model RADAC V5 cleared in K260509

External CT mean DSC, medium structures

0.84 DSC

  • EndpointMean Dice similarity coefficient across externally reviewed medium CT structures
  • PopulationExternal CT image sets described in the K260509 validation summary
  • Tested versionAutoContour Model RADAC V5 cleared in K260509

External CT mean DSC, large structures

0.93 DSC

  • EndpointMean Dice similarity coefficient across externally reviewed large CT structures
  • PopulationExternal CT image sets described in the K260509 validation summary
  • Tested versionAutoContour Model RADAC V5 cleared in K260509

External CT reviewer average

4.37 points on 1-5 scale

  • EndpointAverage clinical-expert rating across CT structure models; 5 meant no edits and 1 meant full manual re-contouring
  • PopulationExternal CT review image sets in the K260509 validation summary
  • Tested versionAutoContour Model RADAC V5 cleared in K260509

External MR mean DSC, small structures

0.71 DSC

  • EndpointMean Dice similarity coefficient across externally reviewed small MR structures
  • PopulationExternal MR brain, pelvis, and HDR structure image sets described in K260509
  • Tested versionAutoContour Model RADAC V5 cleared in K260509

External MR mean DSC, medium structures

0.78 DSC

  • EndpointMean Dice similarity coefficient across externally reviewed medium MR structures
  • PopulationExternal MR brain, pelvis, and HDR structure image sets described in K260509
  • Tested versionAutoContour Model RADAC V5 cleared in K260509

External MR reviewer average

4.3 points on 1-5 scale

  • EndpointAverage clinical-expert rating across MR structure models; 5 meant no edits and 1 meant full manual re-contouring
  • PopulationExternal MR review image sets in the K260509 validation summary
  • Tested versionAutoContour Model RADAC V5 cleared in K260509

Older-version mean contouring time saved

36.6 minutes

  • EndpointMean time saved across the tested breast, head-and-neck, lung, and prostate contour sets after correction
  • PopulationTiming subset of three cases from an 80-patient, five-vendor evaluation
  • Tested versionAutoContour v1.0.25.0 tested in April 2022; not RADAC V5

Older-version average physician score

1.96 points on 1-5 scale

  • EndpointAverage physician score for Radformation contours; lower scores indicated fewer required changes
  • PopulationSixteen organs from 47 patients, reviewed by at least three physicians
  • Tested versionAutoContour v2.2.8; not RADAC V5

K260509 AutoContour Model RADAC V5 verification and validation

  • DesignManufacturer nonclinical validation using held-out training-test partitions, external CT and MR datasets, size-stratified DSC criteria, clinical-expert Likert review, and existing-model regression tests
  • PopulationCT and MR structures across head and neck, thorax, abdomen, and pelvis, with data from several institutions and countries
  • Scopeexact submission
  • Tested versionAutoContour Model RADAC V5; regression tables identify AutoContour v2.7
  • IndependenceSponsor or vendor study

K260509

The FDA summary reports favorable category averages but also structure-level variability, one external MR structure below its DSC criterion, and no patient-outcome study.

A clinical evaluation of the performance of five commercial artificial intelligence contouring systems for radiotherapy

  • DesignIndependent single-center multi-vendor benchmark against manually drawn expert contours with geometric metrics and correction-time measurement
  • Population80 patients: 20 breast, 20 head and neck, 20 lung, and 20 prostate; 45 structures
  • Scopeproduct family
  • Tested versionAutoContour v1.0.25.0 tested in April 2022
  • Samplen=80
  • Sites1
  • IndependenceIndependent study

PMID 37601695

The authors reported no commercial or financial conflicts and acknowledged vendor support and guidance. Timing estimates used a three-patient subset and cannot be transferred to V5 or another site.

Evaluation of multiple-vendor AI autocontouring solutions

  • DesignIndependent single-center blinded physician review and geometric comparison of three commercial CT autocontouring systems against approved physician contours
  • PopulationSixteen organs, ten patients per organ, 47 distinct patients, and at least three physician reviewers per contour
  • Scopeproduct family
  • Tested versionAutoContour v2.2.8
  • Samplen=47
  • Sites1
  • IndependenceIndependent study

PMID 38822385

The study found generally comparable performance but documented poor results with unusual anatomy and local contour-definition differences. It informed implementation across five facilities, but it did not test V5.

Evaluation and failure analysis of four commercial deep learning-based autosegmentation software for abdominal organs at risk

  • DesignIndependent retrospective multi-vendor geometric evaluation with explicit outlier and failure-mode analysis
  • Population111 abdominal cases evaluating liver, stomach, and kidney contours
  • Scopeproduct family
  • Tested versionAutoContour v1.7.11
  • Samplen=111
  • Sites1
  • IndependenceIndependent study

PMID 39946266

Radformation outliers included liver spill into heart or stomach, incomplete stomach contours with barium, and kidney differences driven by whether the renal pelvis was included. The authors reported no conflicts.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K260509 by exact submission identifier.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-02

A zero-result exact-identifier search does not prove that no recall, correction, MAUDE report, or other safety signal exists under a model, catalog, software-version, or product-family identifier. Maintain ongoing FDA and vendor surveillance.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Pricing is recorded, but no exact-product procurement price with a stated offer scope is published in the reviewed sources.

Public pricing
No public list price for AutoContour Model RADAC V5 was found on the reviewed product page. Radformation's license agreement places fees in a customer quote, treats pricing as confidential, and allows additional charges for special support. A quote should separate license basis, delivery-system count, implementation, local or cloud compute, storage and network needs, training, support, upgrades, and renewal terms.
  • Product family
  • Checked 2026-09-02

Reimbursement

Reimbursement
No separate named-product Medicare payment for AutoContour was identified in the reviewed CMS Radiation Oncology Model material. Economic value should be evaluated within the radiation-therapy planning service line using net staff time saved after review and editing, implementation and recurring costs, throughput effects, rework, and downstream plan-quality measures.
  • Service-level, not product-specific
  • Checked 2026-09-02

No product-specific code

No separate named-product payment identified in the reviewed CMS Radiation Oncology Model page

Medicare · United States

This is service-line payment context, not a comprehensive coding, coverage, or procurement determination.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM CT or MR images for contouring or registration and fusion; PET/CT for registration or fusion only; and DICOM RTSTRUCT and REGISTRATION objects as supported inputs.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-02 · K260509 AutoContour Model RADAC V5 510(k) summary

  2. Routing

    Source context, not route validation: The FDA-cleared architecture uses DICOM 3.0 data over TCP/IP, a Windows .NET client, a Windows agent that can monitor network storage for new CT or MR datasets, and a Linux-compatible cloud contouring service. Current AutoContour v2.7 materials also describe direct Eclipse read/write through ESAPI and standalone DICOM workflows; each interface and object type needs site acceptance testing.

    Scope: Exact product version.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-02 · K260509 AutoContour Model RADAC V5 510(k) summary · AutoContour v2.7 product page

  3. AI processing

    Source context, not route validation: K260509 describes a Windows client and local Windows agent connected to a Linux-compatible cloud automatic-contouring service. Current v2.7 marketing also offers cloud-based or local compute resources, but the selected commercial architecture, capacity, network path, and support boundary must be confirmed in the quote and deployment design.

    Scope: Exact product version.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-02 · K260509 AutoContour Model RADAC V5 510(k) summary · AutoContour v2.7 product page

  4. Returned objects

    Source context, not route validation: User-reviewed and editable contours plus DICOM RTSTRUCT, REGISTRATION, and DOSE files for downstream review in a treatment-planning or independent registration-QA system. The FDA summary states that the device has no built-in reporting.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-02 · K260509 AutoContour Model RADAC V5 510(k) summary

  5. Viewer/worklist/report

    Unresolved route: User-reviewed and editable contours plus DICOM RTSTRUCT, REGISTRATION, and DOSE files for downstream review in a treatment-planning or independent registration-QA system. The FDA summary states that the device has no built-in reporting.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-02 · K260509 AutoContour Model RADAC V5 510(k) summary

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
K260509 describes a Windows client and local Windows agent connected to a Linux-compatible cloud automatic-contouring service. Current v2.7 marketing also offers cloud-based or local compute resources, but the selected commercial architecture, capacity, network path, and support boundary must be confirmed in the quote and deployment design.
  • Exact product version
  • Checked 2026-09-02
Integration
The FDA-cleared architecture uses DICOM 3.0 data over TCP/IP, a Windows .NET client, a Windows agent that can monitor network storage for new CT or MR datasets, and a Linux-compatible cloud contouring service. Current AutoContour v2.7 materials also describe direct Eclipse read/write through ESAPI and standalone DICOM workflows; each interface and object type needs site acceptance testing.
  • Exact product version
  • Checked 2026-09-02
Security
Radformation's current license terms state that cloud-processing configurations transmit selected CT or MR images, structures, plan, and dose data after software anonymization, encrypt the data in transit, and delete the imaging-plan data after returning results. The terms place responsibility on the customer to prevent PHI disclosure. Public materials reviewed do not establish the exact V5 authentication, at-rest encryption, retention logging, vulnerability, backup, or incident-response controls for a proposed deployment.
  • Product family
  • Checked 2026-09-02

Obtain a current security package and contract exhibits, validate anonymization with representative DICOM objects, and document identity, access, encryption, logging, retention, subprocessor, recovery, and breach-response controls.

Training
Radformation's current support terms include online educational materials, videos, and a remote training session with new access. NICE states that trained professionals must always review and edit AI autocontours and maintain manual contouring skills. Local training should therefore cover model selection, contouring-guideline alignment, review and editing, unusual-anatomy failure modes, registration QA, DICOM routing, downtime, and escalation.
  • Product family
  • Checked 2026-09-02
Monitoring
Monitor performance by exact software and model version, anatomy, structure, scanner and protocol, patient position, contrast, unusual or postsurgical anatomy, reviewer role, edit time, unusable or missing contours, DICOM transfer failures, registration and dose-export QA, incidents, and adverse events. NICE calls for ongoing error and adverse-event reporting, while independent AutoContour studies show that geometric averages can conceal clinically important outliers and contouring-guideline mismatches.
  • Product family
  • Checked 2026-09-02

Define signed acceptance thresholds and a revalidation trigger for model, software, scanner, protocol, routing, or local contouring-guideline changes.

Exact cleared model scope

K260509 lists 420 CT-based and 62 MR-based contouring models for head and neck, thorax, abdomen, and pelvis. The current product page advertises 480 models across CT, MR, and CBCT; those counts and modality categories are not interchangeable.

exact submission · checked 2026-09-02

Create an enabled-model inventory tied to the installed build, FDA labeling, local anatomy, local contour definitions, and acceptance status.

DICOM and treatment-planning integration

The exact FDA architecture supports CT and MR contouring, PET/CT registration or fusion, DICOM RTSTRUCT and REGISTRATION inputs, and RTSTRUCT, REGISTRATION, and DOSE exports over TCP/IP. Current v2.7 materials add direct Eclipse and standalone DICOM workflow descriptions.

exact product version · checked 2026-09-02

Test each scanner, TPS, service class, object mapping, frame of reference, naming rule, routing path, retry, and failure-recovery workflow.

Human review and local commissioning

The device produces initial contours for review and modification. NICE and independent studies support model-by-model commissioning, trained review, retained manual skills, and special attention to small structures, unusual anatomy, contrast, positioning, and local contouring conventions.

product family · checked 2026-09-02

Commission with representative local cases and predefine accept, edit, reject, and manual-fallback criteria for each enabled model.

Cloud imaging-data governance

Current terms describe software anonymization, encrypted transmission, processing by Radformation, return of results, and deletion of imaging-plan data, while making the customer responsible for preventing PHI disclosure.

product family · checked 2026-09-02

Validate the behavior technically and contractually, including DICOM private tags, burned-in annotations, logs, support access, deletion evidence, and exception handling.

Economic evaluation

The vendor uses quote-based licensing. NICE found autocontouring economics depend on technology cost, professional grade, review and edit time, and true net time saved, with published time endpoints varying substantially.

product family · checked 2026-09-02

Model costs per completed plan and measure total hands-on and elapsed time, edit burden, rejected contours, downstream rework, throughput, and avoided overtime.

Lifecycle monitoring

Current support terms condition support on current releases and installed updates, while NICE calls for ongoing error and adverse-event reporting. Monitoring must remain version-, model-, and anatomy-specific.

product family · checked 2026-09-02

Use controlled update review, regression cases, release acceptance, incident trending, recall surveillance, downtime drills, and rollback criteria.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K260509
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiotherapy Planning Imaging
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-02
Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-02

The FDA summary lists head and neck, thorax, abdomen, and pelvis models rather than a single organ or disease site.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-03-19
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
14Source classes checked
20Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Twenty PubMed records were screened. PMID 38822385 concerns AutoContour v2.2.8 rather than RADAC V5/K260509, and the other records do not establish exact release linkage. No evidence was promoted, and all 20 candidates remain quarantined. The current discovery snapshot contains 20 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, vendor product page, vendor legal documentation, peer reviewed publication, health technology guidance, trial registry, reimbursement policy, fda device recall, fda decision material, literature index, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

12 sources - 3 history items

Source ledger

  1. K260509 AutoContour Model RADAC V5 510(k) summary

    U.S. Food and Drug Administration - Published 2026-03-19 - Accessed 2026-09-02

    Scope: purpose, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, integration, deployment, evidenceSummary, evidenceMetrics, evidenceStudy, implementationCapabilities, softwareVersion

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  6. Radiation Oncology Model

    Centers for Medicare & Medicaid Services - Accessed 2026-09-02

    Scope: reimbursement, radiationTherapyPaymentContext

  7. AutoContour v2.7 product page

    Radformation, Inc. - Accessed 2026-09-02

    Scope: productFamily, integration, deployment, pricingResearch, currentCommercialContext, implementationCapabilities

  8. Radformation Software License Agreement and support terms

    Radformation, Inc. - Accessed 2026-09-02

    Scope: security, training, pricing, monitoring, dataGovernance, implementationCapabilities

  9. Artificial intelligence technologies to aid contouring for radiotherapy treatment planning

    National Institute for Health and Care Excellence - Published 2023-09-27 - Accessed 2026-09-02

    Scope: limitations, training, pricing, evidenceSummary, economics, monitoring, implementationCapabilities

  10. A clinical evaluation of the performance of five commercial artificial intelligence contouring systems for radiotherapy

    Frontiers in Oncology - Published 2023-08-08 - Accessed 2026-09-02

    Scope: evidenceSummary, evidenceStudy, evidenceMetrics, economics, implementationCapabilities

  11. Evaluation of multiple-vendor AI autocontouring solutions

    Radiation Oncology - Published 2024-05-31 - Accessed 2026-09-02

    Scope: evidenceSummary, evidenceStudy, evidenceMetrics, implementationCapabilities

  12. Evaluation and failure analysis of four commercial deep learning-based autosegmentation software for abdominal organs at risk

    Journal of Applied Clinical Medical Physics - Published 2025-02-13 - Accessed 2026-09-02

    Scope: limitations, evidenceSummary, evidenceStudy, evidenceMetrics, monitoring, implementationCapabilities

Research history

  1. K260509 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252188

EMLA (Elekta Evo); EMLA (VersaHD); EMLA (Elekta Harmony Pro); EMLA (Elekta Infintiy); EMLA (Elekta Harmony); EMLA (Elekta Synergy)

Elekta Solutions AB

Authorized purpose: The EMLA family delivers external-beam radiation therapy for adult and pediatric patients with benign, malignant, or metastatic disease. Authorized techniques vary by model: Synergy and Harmony include conventional and fractionated delivery; Infinity and Harmony Pro add SBRT/SABR; Versa HD and Evo also support SRS and specified functional disorders.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2026-01-15
FDA-cleared K253091

ART-Plan+ (v3.1.0)

Therapanacea Sas

Authorized purpose: ART-Plan+ assists trained radiation-therapy professionals with multimodal image review, registration, contouring, and the release-specific planning functions described in K253091. This release combined Annotate, prostate SmartPlan, and AdaptBox for supported head-and-neck, breast or thorax, and male-pelvis offline adaptive workflows, and added structures without changing the core indication.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2025-12-23
FDA-cleared K242748

Oncospace

Oncospace, Inc.

Authorized purpose: Oncospace supports trained radiation therapy professionals with protocol configuration, machine-learning achievable-dose prediction, planning-objective exchange, and plan review across head-and-neck, thoracic, abdominal, and pelvic workflows using locked models.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2025-04-11
FDA-cleared K240398

RayStation 2023B, RayPlan 2023B, RayStation 2024A, RayPlan 2024A, RayStation 2024A SP3, RayPlan 2024A SP3

RaySearch Laboratories AB (PUBL)

Authorized purpose: RayStation and RayPlan releases covered by K240398 are configurable radiotherapy and medical-oncology software that proposes or supports treatment plans from user inputs, with authorized users required to review and approve plans before treatment.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2025-04-04

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history